Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).
NCT03634826 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2020-06-26
Summary
Conduct a prospective study to confirm the value of circulating tumor DNA and its aberrant methylation in longitudinal monitoring of surgical lung cancer patients.
Conditions
- Carcinoma
- Lung Cancer
- NSCLC
- Lung Neoplasm
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Principal Investigators
-
Jun Wang, M.D. · Peking University People's Hospital Thoracic Surgery Department
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-15
- Primary Completion
- 2021-12-31
- Completion
- 2022-01-01
Countries
- China
Study Locations
More Related Trials
-
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222 ·Status: RECRUITING
-
Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer
NCT02645318 ·Status: COMPLETED
-
Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
NCT02696525 ·Status: UNKNOWN
-
Study of Tumor Samples From Patients With Lung Cancer
NCT00900328 ·Status: COMPLETED
-
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
NCT04413656 ·Status: UNKNOWN ·Phase: NA
-
Non-Invasive ctDNA Methylation Detection for Lung Nodule Patients
NCT03685669 ·Status: UNKNOWN
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156 ·Status: COMPLETED
-
Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer
NCT03317080 ·Status: UNKNOWN
-
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
NCT02833467 ·Status: UNKNOWN
-
ctDNA as a Biomarker for Treatment in Advanced NSCLC
NCT05486988 ·Status: UNKNOWN
-
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
NCT02907606 ·Status: UNKNOWN
-
Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA
NCT03499678 ·Status: TERMINATED
-
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
NCT03926260 ·Status: COMPLETED ·Phase: NA
-
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
NCT03651986 ·Status: UNKNOWN
-
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
NCT02946216 ·Status: UNKNOWN
-
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
NCT05167604 ·Status: UNKNOWN
-
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
NCT05066945 ·Status: NOT_YET_RECRUITING
-
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
NCT03059641 ·Status: COMPLETED
-
Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System
NCT04454853 ·Status: COMPLETED
-
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
NCT04238130 ·Status: COMPLETED
-
Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy
NCT04741633 ·Status: UNKNOWN
-
ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy
NCT05822284 ·Status: NOT_YET_RECRUITING
-
The Tracking Molecular Evolution for NSCLC (T-MENC) Study
NCT03838588 ·Status: UNKNOWN
-
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
NCT04814407 ·Status: RECRUITING
-
Application of Methylation Markers in Early Detection and MRD Monitoring of Lung Cancer
NCT07257458 ·Status: RECRUITING